ATS 2026: Mixed results for Sanofi/Regeneron’s itepekimab cloud COPD prospects

Failure of AERIFY-2 to show clear benefit in COPD places itepekimab on the backfoot against AstraZeneca’s tozorakimab. Failure of AERIFY-2 to show clear benefit in COPD places itepekimab on the backfoot against AstraZeneca’s tozorakimab. Itepekimab saddled with unclear clinical results for COPD in former smokers at ATS 2026. Credit: Jo Panuwat D/Shutterstock.com On 16 May, during the 2026 American Thoracic Society (ATS) International Conference, Sanofi and Regeneron presented new safety and efficacy data from their AERIFY-1 (NCT04701983) and AERIFY-2 (NCT04751487) Phase III clinical trials, evaluating itepekimab, a fully human interleukin-33 (IL-33) monoclonal antibody (mAb), in former smokers with moderate to…

Source: Clinical Trials Arena